Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
13 nov. 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression
12 nov. 2024 08h11 HE
|
Magstim EGI
FDA clears Magstim INSPIRE Transcranial Magnetic Stimulation TMS system to treat patients with Depression, OCD, Anxious Depression
Acuitive Technologies Receives FDA 510(k) Clearance for CITREPORE™, A New Synthetic Bioactive Bone Void Filler for Orthopedic Procedures
12 nov. 2024 08h00 HE
|
Acuitive Technologies
Acuitive Technologies announced the FDA 510(k) clearance of CITREPORE™, a new synthetic bioactive bone void filler for orthopedic procedures.
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
08 nov. 2024 16h23 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07 nov. 2024 16h05 HE
|
CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
04 nov. 2024 07h00 HE
|
CytoSorbents
CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA
31 oct. 2024 15h28 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research (FSR) hosts Externally Led Patient-Focused Drug Development (EL-PFDD) meeting for Sarcoidosis
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
29 oct. 2024 07h48 HE
|
Praxis Bioresearch, Inc.
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
FDA Grants De Novo Marketing Authorization for the Distalmotion Dexter® Surgical Robot
28 oct. 2024 05h00 HE
|
Distalmotion
Lausanne, Switzerland, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Distalmotion has been granted De Novo approval by the U.S. Food and Drug Administration (FDA) to market the Dexter Surgical Robot for adult...
Quality Smart Solutions Launches GRAS Experts to Protect Against Food Safety Risks
25 oct. 2024 12h24 HE
|
Quality Smart Solutions Inc.
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- In light of McDonald’s recent recall of Quarter Pounders due to E. coli contamination, the need for stringent oversight on food ingredients has never been...